Mar 17, 2025 / 09:00PM GMT
Operator
Hello, everyone, and welcome to the FibroGen fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
Now it's my pleasure to turn the call over to Joanne Geller. The floor is yours.
Joanne Geller - LifeSci Advisors - Investor Relations
Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss FibroGenâs fourth quarter and full year 2024 financial and business results. Iâm Joanne Geller from LifeSci Advisors. Joining me on todayâs call are Thane Wettig, our Chief Executive Officer; and David DeLucia, our Chief Financial Officer.
Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on todayâs call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas, financial guidance the initiation, enrollment, design, conduct, and results of clinical trials our regulatory strategies
Q4 2024 FibroGen Inc Earnings Call Transcript
Mar 18, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers